Midostaurin

Overview

Midostaurin is a multi-targeted kinase inhibitor used in the treatment of acute myeloid leukemia and certain other hematological malignancies. It works by interfering with the action of FLT3 and other kinases involved in cancer cell proliferation.

API suppliers (9)

Suppliers of Midostaurin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• DR REDDYS LABORATORIES LTD1 active DMF GMP on record
• CONCORD BIOTECH LTDIndia1 active DMF GMP on record
• MSN Laboratories Private LimitedIndia1 active DMF GMP on record
• PROCOS SPAItaly1 active DMF GMP on record
• TAPI NL BVNetherlands1 active DMF
• HUBEI HONCH PHARMACEUTICAL CO LTD1 active DMF
• Hetero Labs LimitedIndia1 active DMF GMP on record
• CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF GMP on record
• BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTDChina

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Midostaurin expires 2 Dec 2030. Generic API sourcing typically opens up once these lapse.

Therapeutic areas